On June 10, 2026 Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics, reported updated clinical findings from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with its lead investigational product candidate, ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE), following presentation at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 81-patient experience represents one of the largest clinical datasets reported to date for an albumin-binding peptide receptor radionuclide therapy (PRRT) and provides growing evidence that EBTATE may offer a differentiated and potentially best-in-class profile compared with conventional PRRT approaches.
Key Clinical Highlights from 81 Treated GEP-NET Patients
Approximately 8-fold higher tumor uptake compared with conventional PRRT
50% objective response rate (ORR)
100% disease control rate (DCR)
36-month median progression-free survival (PFS)
No observed kidney toxicity through one year of follow-up
Equivalent renal absorbed dose with or without amino acid infusion
Potential two-cycle treatment regimen versus the conventional four-cycle PRRT
Clinical activity achieved using only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT
The findings further validate MTTI’s proprietary Evans Blue (EB) technology platform, which utilizes reversible albumin binding to extend circulation time, enhance tumor uptake, and increase tumor retention. Preclinical studies have demonstrated up to 26-fold higher tumor retention compared with conventional radiopharmaceutical approaches, supporting broad applicability across multiple radionuclides, targeting vectors, and tumor types.
"The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform," said Chris Pak, Chairman and Chief Executive Officer of MTTI. "By improving tumor delivery and retention while requiring only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT, the platform has the potential to enhance the therapeutic index of radiopharmaceuticals across multiple cancers and with both beta- and alpha-emitting radionuclides. The combination of enhanced tumor uptake, prolonged tumor retention, favorable clinical responses, and robust safety observations supports the continued development of EBTATE and highlights the broader potential of the Evans Blue platform to improve targeted radiotherapeutics across a wide range of solid tumors."
"EBTATE achieved markedly higher tumor uptake and longer tumor retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile," said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center and recipient of the 2026 Castle Connolly America’s Top Doctor Award. "The ability to deliver higher radiation doses to tumors with significantly lower administered radioactivity highlights the potential of this albumin-binding approach to improve the therapeutic index of PRRT. This data from NET patients supports continued clinical development and further evaluation of a streamlined treatment regimen."
(Press release, Molecular Targeting Technologies, JUN 10, 2026, View Source [SID1234666552])